First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature

Culp, 2020, Recent global patterns in prostate cancer incidence and mortality rates, Eur Urol, 77, 38, 10.1016/j.eururo.2019.08.005 Cooperberg, 2010, Time trends and local variation in primary treatment of localized prostate cancer, J Clin Oncol, 28, 1117, 10.1200/JCO.2009.26.0133 Morgan, 2014, A risk-adjusted definition of biochemical recurrence after radical prostatectomy, Prostate Cancer Prostatic Dis, 17, 174, 10.1038/pcan.2014.5 Cornford, 2021, EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer, Eur Urol, 79, 263, 10.1016/j.eururo.2020.09.046 Lowrance, 2021, Advanced prostate cancer: AUA/ASTRO/SUO guideline part I, J Urol, 205, 14, 10.1097/JU.0000000000001375 van den Bergh, 2016, Role of hormonal treatment in prostate cancer patients with nonmetastatic disease recurrence after local curative treatment: a systematic review, Eur Urol, 69, 802, 10.1016/j.eururo.2015.11.023 Virgo, 2021, Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update, J Clin Oncol, 39, 1274, 10.1200/JCO.20.03256 Kyriakopoulos, 2018, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial, J Clin Oncol, 36, 1080, 10.1200/JCO.2017.75.3657 Deek, 2021, The mutational landscape of metastatic castration-sensitive prostate cancer: the spectrum theory revisited, Eur Urol, 80, 632, 10.1016/j.eururo.2020.12.040 Stopsack, 2020, Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer, Clin Cancer Res, 26, 3230, 10.1158/1078-0432.CCR-20-0168 Sweeney, 2015, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747 Gravis, 2016, Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial, Eur Urol, 70, 256, 10.1016/j.eururo.2015.11.005 Gravis, 2018, Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies, Eur Urol, 73, 847, 10.1016/j.eururo.2018.02.001 Abdel-Rahman, 2018, Impact of prior local treatment on the outcomes of metastatic hormone-sensitive prostate cancer: secondary analysis of a randomized controlled trial, Clin Genitourin Cancer, 16, 466, 10.1016/j.clgc.2018.07.007 James, 2016, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet, 387, 1163, 10.1016/S0140-6736(15)01037-5 Sweeney, 2021, Overall survival of men with metachronous metastatic hormone-sensitive prostate cancer treated with enzalutamide and androgen deprivation therapy, Eur Urol, 80, 275, 10.1016/j.eururo.2021.05.016 Davis, 2019, Enzalutamide with standard first-line therapy in metastatic prostate cancer, N Engl J Med, 381, 121, 10.1056/NEJMoa1903835 Armstrong, 2019, ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer, J Clin Oncol, 37, 2974, 10.1200/JCO.19.00799 Chi, 2019, Apalutamide for metastatic, castration-sensitive prostate cancer, N Engl J Med, 381, 13, 10.1056/NEJMoa1903307 Chi, 2021, Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study, J Clin Oncol, 39, 2294, 10.1200/JCO.20.03488 James, 2017, Abiraterone for prostate cancer not previously treated with hormone therapy, N Engl J Med, 377, 338, 10.1056/NEJMoa1702900 Fizazi, 2017, Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer, N Engl J Med, 377, 352, 10.1056/NEJMoa1704174 Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, BMJ, 339, b2535, 10.1136/bmj.b2535 Ouzzani, 2016, Rayyan—a web and mobile app for systematic reviews, Syst Rev, 5, 210, 10.1186/s13643-016-0384-4 Guyatt, 2008, GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, BMJ, 336, 924, 10.1136/bmj.39489.470347.AD Sterne, 2019, RoB 2: a revised tool for assessing risk of bias in randomised trials, BMJ, 366, l4898, 10.1136/bmj.l4898 Knoll, 2018, Key steps in conducting systematic reviews for underpinning clinical practice guidelines: methodology of the European Association of Urology, Eur Urol, 73, 290, 10.1016/j.eururo.2017.08.016 Smith, 2022, Darolutamide and survival in metastatic, hormone-sensitive prostate cancer, N Engl J Med, 386, 1132, 10.1056/NEJMoa2119115 Autio, 2021, Randomized phase 2 trial of abiraterone acetate plus prednisone, degarelix, or the combination in men with biochemically recurrent prostate cancer after radical prostatectomy, Eur Urol Open Sci, 34, 70, 10.1016/j.euros.2021.09.015 Casas, 2017, Intermittent versus continuous androgen deprivation therapy to biochemical recurrence after external beam radiotherapy: a phase 3 GICOR study, Clin Transl Oncol, 19, 373, 10.1007/s12094-016-1538-5 Morris, 2021, Phase 3 randomized controlled trial of androgen deprivation therapy with or without docetaxel in high-risk biochemically recurrent prostate cancer after surgery (TAX3503), Eur Urol Oncol, 4, 543, 10.1016/j.euo.2021.04.008 Schweizer, 2013, Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy, Ann Oncol, 24, 2881, 10.1093/annonc/mdt335 Francini, 2018, Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC), Prostate, 78, 889, 10.1002/pros.23645 Azad, 2021, Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with de novo (M1) metastatic hormone-sensitive prostate cancer (mHSPC) versus progression to mHSPC (M0): post hoc analysis of the phase III ARCHES trial, J Clin Oncol, 39, 102, 10.1200/JCO.2021.39.6_suppl.102 Duchesne, 2016, Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01–03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial, Lancet Oncol, 17, 727, 10.1016/S1470-2045(16)00107-8 Duchesne, 2017, Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01–03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial, Lancet Oncol, 18, 1192, 10.1016/S1470-2045(17)30426-6 Fu, 2017, Mortality and androgen deprivation therapy as salvage treatment for biochemical recurrence after primary therapy for clinically localized prostate cancer, J Urol, 197, 1448, 10.1016/j.juro.2016.12.086 Hamstra, 2015, Impact of biochemical failure classification on clinical outcome: a secondary analysis of radiation therapy oncology group 9202 and 9413, Cancer, 121, 844, 10.1002/cncr.29146 Hearn, 2016, HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study, Lancet Oncol, 17, 1435, 10.1016/S1470-2045(16)30227-3 Hearn, 2018, Association of HSD3B1 genotype with response to androgen-deprivation therapy for biochemical recurrence after radiotherapy for localized prostate cancer, JAMA Oncol, 4, 558, 10.1001/jamaoncol.2017.3164 Marshall, 2021, Timing of androgen deprivation treatment for men with biochemical recurrent prostate cancer in the context of novel therapies, J Urol, 206, 623, 10.1097/JU.0000000000001797 Park, 2018, Impact of early salvage androgen deprivation therapy in localized prostate cancer after radical prostatectomy: a propensity score matched analysis, Yonsei Med J, 59, 580, 10.3349/ymj.2018.59.5.580 Ravi, 2018, Outcomes and prognostic factors in men receiving androgen deprivation therapy for prostate cancer recurrence after radical prostatectomy, J Urol, 200, 1075, 10.1016/j.juro.2018.04.070 Crook, 2012, Intermittent androgen suppression for rising PSA level after radiotherapy, N Engl J Med, 367, 895, 10.1056/NEJMoa1201546 Klotz, 2015, Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT, J Clin Oncol, 33, 1151, 10.1200/JCO.2014.58.2973 Maru, 2018, Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy, PLoS One, 13, e0197252, 10.1371/journal.pone.0197252 Tremblay, 2021, Interpreting testosterone and concomitant prostate specific antigen values during androgen deprivation therapy for recurrent prostate cancer, J Urol, 206, 1166, 10.1097/JU.0000000000001946 Oudard, 2019, Effect of adding docetaxel to androgen-deprivation therapy in patients with high-risk prostate cancer with rising prostate-specific antigen levels after primary local therapy: a randomized clinical trial, JAMA Oncol, 5, 623, 10.1001/jamaoncol.2018.6607 Spetsieris, 2021, Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer, Eur J Cancer, 157, 259, 10.1016/j.ejca.2021.06.017 Attard, 2022, Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol, Lancet, 399, 447, 10.1016/S0140-6736(21)02437-5 Antonarakis, 2012, Changes in PSA kinetics predict metastasis-free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials, Cancer, 118, 1533, 10.1002/cncr.26437 Beer, 2011, Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer, Clin Cancer Res, 17, 4558, 10.1158/1078-0432.CCR-10-3223 Klayton, 2011, PSA doubling time predicts for the development of distant metastases for patients who fail 3DCRT or IMRT using the phoenix definition, Pract Radiat Oncol, 1, 235, 10.1016/j.prro.2011.02.003 Calais, 2019, (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial, Lancet Oncol, 20, 1286, 10.1016/S1470-2045(19)30415-2 Morigi, 2015, Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy, J Nucl Med, 56, 1185, 10.2967/jnumed.115.160382 Ost, 2018, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial, J Clin Oncol, 36, 446, 10.1200/JCO.2017.75.4853 Phillips, 2020, Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial, JAMA Oncol, 6, 650, 10.1001/jamaoncol.2020.0147 Foster, 2014, Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy, Radiat Oncol, 9, 245, 10.1186/s13014-014-0245-z Garcia-Albeniz, 2015, Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study, Eur J Cancer, 51, 817, 10.1016/j.ejca.2015.03.003 Kim, 2013, Defining the optimal approach to the patient with postradiation prostate-specific antigen recurrence using outcome data from a prospective randomized trial, Cancer, 119, 3280, 10.1002/cncr.28202 Matsumoto, 2014, Optimal timing of hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy, Med Oncol, 31, 45, 10.1007/s12032-014-0045-1 McKay, 2016, A randomized phase II trial of short-course androgen deprivation therapy with or without bevacizumab for patients with recurrent prostate cancer after definitive local therapy, J Clin Oncol, 34, 1913, 10.1200/JCO.2015.65.3154 Mydin, 2013, Early salvage hormonal therapy for biochemical failure improved survival in prostate cancer patients after neoadjuvant hormonal therapy plus radiation therapy—a secondary analysis of Irish Clinical Oncology Research Group 97–01, Int J Radiat Oncol Biol Phys, 85, 101, 10.1016/j.ijrobp.2012.03.001 Souhami, 2010, Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a secondary analysis of Radiation Therapy Oncology Group 85–31, Int J Radiat Oncol Biol Phys, 78, 1301, 10.1016/j.ijrobp.2009.10.007 Taguchi, 2014, Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer, BMC Urol, 14, 81, 10.1186/1471-2490-14-81